In 2016, a per-prescription cost-sharing cap was introduced for non-catastrophic plans offered on the Patient Protection and Affordable Care Act health exchange in California’s individual and small group markets. This report analyzes the impact of this regulation on projected prescription drug spending across the California individual and small group markets.The analysis looks at two components of a premium increase related to this benefit change.
This report was commissioned by The Biotechnology Innovation Organization.
The impact of California’s prescription drug cost-sharing cap
This report analyzes the impact of the per-prescription cost-sharing cap for non-catastrophic plans on projected prescription drug spending across the California individual and small group markets.